How to improve patient’s awareness about the risk of cancer-associated thrombosis
Although patients with cancer have a four-to-five-fold increased risk of venous thromboembolism (VTE) compared with the...
Prevention
PODCAST. Building a CAT Clinic: Real-World Systems Approaches to Prevention and Treatment. Waiting for ICTHIC 2022
Cancer-associated thrombosis (CAT) is an important and increasingly common complication of cancer and cancer...
Prognostic markers in patients with advanced cancer. Waiting for ICTHIC 2022
Estimation of prognosis is of utmost importance when managing patients with advanced cancer: it helps make decisions...
What information should be given to patients with cancer, and when should it be given on the cancer care pathway?
During the ICTHIC webinar “Joint forces: the Patient & the Multi-disciplinary Team working together to...
Modeling predictors and outcomes in myeloproliferative neoplasms and thrombosis
Myeloproliferative neoplasms (MPNs) are characterized by clonal expansion of abnormal hematopoietic stem cells, which...
Looking for a reliable tool to identify hypercoagulant markers for cancer risk and prognosis: the HYPERCAN study
The HYPERCAN (HYPERcoagulation in CANcer) study (registered at www.clinicaltrials.gov; NCT02622815) is an ongoing,...
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
The American Society of Clinical Oncology just published the new recommendations regarding VTE prophylaxis and...
Risk factors and prevention of venous thromboembolism in ambulatory cancer patients requiring chemotherapy
Epidemiology and risk factors Venous thromboembolism (VTE) is a burdensome and frequent complication in patients with...